Leland Stanford Junior University

Bolt Biotherapeutics, Inc.

Lumen Therapeutics, LLC

Becton Dickinson and Company Limited

Cetus Corporation

Other

Dendreon Corporation

Genelabs, Incorporated

The Board of Trustees of Leeland Stanford Jr. Univ.

Edgar George Engleman

Wayne Godfrey

Mark Smith

James W Larrick

Brian Salvatore Safina

Wayne R Godfrey

Khoa Dinh Nguyen

Jonathan B Rothbard

Arthur Lee

David Y Jackson

David W Buck

C Garrison Fathman

Paul Leo McGrane

Steven K Foung

Shelley Erin Ackerman

Erik Kreider

Michael Nathaniel Alonso

Justin A Kenkel

F Carl Grumet

Samuel D Banister

Hweixian Leong Penny

Samuel Strober

Robert Lowsky

Curtis L Ruegg

Ronald Levy

Reiner Laus

Ronald F Van Vollenhoven

Frank C Grumet

Nupur Bhattacharya

Andrew A Raubitschek

Andrew R Raubitschek

Linda B Rabin

Judith A Blunt

Ruggero Pardi

Jeffrey R Bender

James L McGuire

Alberto Rivas

Linda R McGuire, Administratrix

James L McGuire, Deceased

Masaru Takamizawa

Anita Mehta

Sergiusz Markowicz

Francesco Fagnoni

Miriam Merad

Lawrence H Fong

Claudia Benike

Frank Hsu

A genus of compounds encompassed by formula (III) and their use is disclosed: The compounds activate Ppargc1a and, as a consequence, are useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and a demyelinating disease.

2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases

The invention provides an immunoconjugate comprising an antibody construct which includes an antigen binding domain and an Fc domain, an adjuvant moiety, and a linker, wherein each adjuvant moiety is covalently bonded to the antibody via the linker. Methods for treating cancer with the immunoconjugates of the invention are also described.

Antibody adjuvant conjugates

Residual, refractory or relapsed cancer is treated by immunostimulation in the presence of allogeneic immune effector cells, optimally in combination with radiation therapy. The methods of the disclosure induce a systemic allogeneic anti-tumor immune response that results in tumor regression in untreated sites of disease, i.e. non-injected, non-irradiated, etc.

Methods for cancer treatment

The invention provides an immunoconjugate of formula: or pharmaceutically acceptable salt thereof, wherein subscript r is an integer from 1 to 10, subscript n is an integer from about 2 to about 25, and 'Ab' is an antibody construct that has an antigen binding domain that binds HER2. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.

Immunoconjugates targeting HER2

The compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol: and its use are disclosed. The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.

The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

Method for treating neurodegenerative diseases

The compound 2-(3-tert-Butylphenyl)-4,6-difluoro-1H-benzo[d]imidazole and its use are disclosed: The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.

2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases

The present invention is directed to a method for preventing and/or treating aging-related cognitive impairment in the central nervous system. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.

Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation

An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation.

Reversing intestinal inflammation by inhibiting retinoic acid metabolism

Growing community of inventors

Atherton, CA, United States of America

Edgar George Engleman